<DOC>
	<DOCNO>NCT01224093</DOCNO>
	<brief_summary>This prospective observational study evaluate safety MabThera/Rituxan ( rituximab ) combination chemotherapy patient previously untreated relapsed/refractory B cell-lineage chronic lymphocytic leukaemia . Data collect patient 6-12 month , depend prescribe chemotherapy regimen .</brief_summary>
	<brief_title>An Observational Study Safety Profile MabThera/Rituxan ( Rituximab ) Combination With Chemotherapy Patients With B Cell-lineage Chronic Lymphocytic Leukaemia ( MABERYC )</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Adult patient , &gt; /= 18 year age B celllineage chronic lymphocytic leukaemia ( BCLL ) Prescribed MabThera/Rituxan combination chemotherapy accord approve SMPC Informed consent data collection Treatment market nonmarketed drug substance experimental therapy within 4 week prior first dose study drug participation clinical trial within 30 day prior enter study Any tumour disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>